CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation

[1]  E. Urbańska,et al.  Kynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target? , 2023, Cells.

[2]  E. Tantsis,et al.  Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids , 2022, EBioMedicine.

[3]  V. Apostolopoulos,et al.  The Role of Tryptophan Metabolites in Neuropsychiatric Disorders , 2022, International journal of molecular sciences.

[4]  L. Vécsei,et al.  Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System , 2022, Cells.

[5]  L. Vécsei,et al.  Editorial of Special Issue ‘Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection’ , 2022, International journal of molecular sciences.

[6]  Ukpong B. Eyo,et al.  Microglia and Neurodevelopmental Disorders. , 2022, Annual review of neuroscience.

[7]  V. Coppens,et al.  LC-MS biomarker diagnostics for neuroinflammatory disorders , 2022, EBioMedicine.

[8]  G. Guillemin,et al.  Development of a translational inflammation panel for the quantification of cerebrospinal fluid Pterin, Tryptophan-Kynurenine and Nitric oxide pathway metabolites , 2022, EBioMedicine.

[9]  L. Vécsei,et al.  Editorial: Multiple Implications of the Kynurenine Pathway in Inflammatory Diseases: Diagnostic and Therapeutic Applications , 2022, Frontiers in Immunology.

[10]  J. Rho,et al.  Seizure modulation by the gut microbiota and tryptophan-kynurenine metabolism in an animal model of infantile spasms , 2022, EBioMedicine.

[11]  B. Brew,et al.  Recent advances in clinical trials targeting the kynurenine pathway. , 2021, Pharmacology & therapeutics.

[12]  J. Honnorat,et al.  Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis , 2021, International journal of molecular sciences.

[13]  Y. Crow,et al.  The type I interferonopathies: 10 years on , 2021, Nature Reviews Immunology.

[14]  L. Vécsei,et al.  Monitoring the kynurenine system: Concentrations, ratios or what else? , 2021, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[15]  R. Dale,et al.  Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease , 2021, Clinical & translational immunology.

[16]  S. Landi,et al.  Neuroinflammation: A Signature or a Cause of Epilepsy? , 2021, International journal of molecular sciences.

[17]  L. Vécsei,et al.  Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway , 2021, Biomedicines.

[18]  J. O'Connor,et al.  Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications , 2021, Cells.

[19]  C. Wouters,et al.  From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8 , 2021, Frontiers in Immunology.

[20]  J. Rieckmann,et al.  Proteomics reveals distinct mechanisms regulating the release of cytokines and alarmins during pyroptosis. , 2021, Cell reports.

[21]  N. Curtis,et al.  Bacterial Meningitis in the Absence of Pleocytosis in Children: A Systematic Review. , 2021, The Pediatric infectious disease journal.

[22]  I. Lazar,et al.  Systems-Level Proteomics Evaluation of Microglia Response to Tumor-Supportive Anti-Inflammatory Cytokines , 2021, bioRxiv.

[23]  Lei Liu,et al.  Cytokines/Chemokines: Potential Biomarkers for Non-paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis , 2020, Frontiers in Neurology.

[24]  R. Dale,et al.  Cerebrospinal fluid metabolites in tryptophan‐kynurenine and nitric oxide pathways: biomarkers for acute neuroinflammation , 2020, Developmental medicine and child neurology.

[25]  L. Vécsei,et al.  Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway , 2020, International journal of molecular sciences.

[26]  L. D’Adamio,et al.  Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use , 2020, Journal of personalized medicine.

[27]  J. Toldi,et al.  Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines , 2020, International journal of molecular sciences.

[28]  Nguyen Phuoc Long,et al.  Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine , 2020, Metabolites.

[29]  L. Vécsei,et al.  Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism , 2020, Molecules.

[30]  M. Krumbholz,et al.  Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases , 2019, Journal of Neuroinflammation.

[31]  P. Naudé,et al.  Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target , 2019, Front. Immunol..

[32]  B. Anlar,et al.  Elevated quinolinic acid levels in cerebrospinal fluid in subacute sclerosing panencephalitis , 2019, Journal of Neuroimmunology.

[33]  K. Kothur,et al.  Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection‐related epilepsy syndrome and febrile status epilepticus , 2019, Epilepsia.

[34]  Y. Shao,et al.  Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease , 2019, Molecular Neurodegeneration.

[35]  M. Edwards,et al.  Functional neurological disorders: acute presentations and management. , 2018, Clinical medicine.

[36]  S. Sengupta,et al.  Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings , 2018, The Journal of Nutritional Biochemistry.

[37]  S. Gieseg,et al.  Neopterin, Inflammation, and Oxidative Stress: What Could We Be Missing? , 2018, Antioxidants.

[38]  L. Facci,et al.  An Inflammation-Centric View of Neurological Disease: Beyond the Neuron , 2018, Front. Cell. Neurosci..

[39]  Berislav V. Zlokovic,et al.  Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.

[40]  A. Hoeflich,et al.  Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions , 2018, Front. Immunol..

[41]  P. Vodička,et al.  Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research , 2017, International journal of molecular sciences.

[42]  A. Larsson,et al.  High levels of cerebrospinal fluid chemokines point to the presence of neuroinflammation in peripheral neuropathic pain: a cross-sectional study of 2 cohorts of patients compared with healthy controls , 2017, Pain.

[43]  M. Nybo,et al.  Cerebrospinal fluid pleocytosis level as a diagnostic predictor? A cross-sectional study , 2017, BMC Clinical Pathology.

[44]  G. Scott,et al.  Microglial Activation in Traumatic Brain Injury , 2017, Front. Aging Neurosci..

[45]  T. Benfield,et al.  Cerebrospinal fluid pleocytosis in infectious and noninfectious central nervous system disease , 2017, Medicine.

[46]  Gilles J. Guillemin,et al.  Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases , 2017, Neuropharmacology.

[47]  N. Braidy,et al.  Kynurenine pathway metabolism and neuroinflammatory disease , 2017, Neural regeneration research.

[48]  Xuetao Cao,et al.  Cellular and molecular regulation of innate inflammatory responses , 2016, Cellular & Molecular Immunology.

[49]  E. Tantsis,et al.  Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis , 2016, PloS one.

[50]  R. Dale,et al.  Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. , 2016, Autoimmunity reviews.

[51]  Kalyani Kansal,et al.  The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. , 2015, The Psychiatric clinics of North America.

[52]  E. Yan,et al.  Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans , 2015, Journal of Neuroinflammation.

[53]  D. Pennington,et al.  Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. , 2014, Biochimica et biophysica acta.

[54]  A. Venkatesan,et al.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  J. Pedraza-Chaverri,et al.  Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets , 2013, Oxidative medicine and cellular longevity.

[56]  M. Philipp,et al.  Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain , 2013, Mediators of inflammation.

[57]  A. Ghezzi,et al.  International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions , 2013, Multiple sclerosis.

[58]  K. Spindler,et al.  Viral disruption of the blood-brain barrier. , 2012, Trends in microbiology.

[59]  G. Guillemin.  Quinolinic acid, the inescapable neurotoxin , 2012, The FEBS journal.

[60]  M. Vizcaychipi,et al.  Central nervous system inflammation in disease related conditions: Mechanistic prospects , 2012, Brain Research.

[61]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[62]  R. Dale,et al.  Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation , 2009, Developmental medicine and child neurology.

[63]  N. Rothwell,et al.  The role of inflammation in CNS injury and disease , 2006, British journal of pharmacology.

[64]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[65]  T. Jernigan,et al.  Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. , 2001, Brain : a journal of neurology.

[66]  E. Sinz,et al.  Quinolinic Acid is Increased in CSF and Associated with Mortality after Traumatic Brain Injury in Humans , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[67]  G. G. Lloyd,et al.  Acute behaviour disturbances. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[68]  T. Stone,et al.  Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.

[69]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[70]  K. Kothur,et al.  CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. , 2016, Cytokine.

[71]  U. Zettl,et al.  Autoimmune disorders affecting both the central and peripheral nervous system. , 2012, Autoimmunity reviews.

[72]  G. Janka,et al.  Familial and acquired hemophagocytic lymphohistiocytosis. , 2012, Annual review of medicine.

[73]  Tallie Z. Baram,et al.  The role of inflammation in epilepsy , 2011, Nature Reviews Neurology.

[74]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.